This HTML5 document contains 143 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1182/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33364359
rdf:type
wikibase:Item
schema:description
مقالهٔ علمی naučni članak wissenschaftlicher Artikel vetenskaplig artikel vědecký článek บทความทางวิทยาศาสตร์ 2004年论文 artikulong pang-agham 2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված 2004年論文 tudományos cikk مقالة علمية artigo científico (publicado na 2004) 2004年论文 article scientific vedecký článok научна статия სამეცნიერო სტატია 2004 nî lūn-bûn scienca artikolo bilimsel makale 2004年论文 article científic articolo scientifico artículo científico publicado en 2004 article scientifique (publié 2004) teaduslik artikkel scientific article vitskapeleg artikkel artigo científico (publicado na 2004) artikull shkencor mokslinis straipsnis 2004年論文 سائنسی مضمون 2004年论文 videnskabelig artikel (udgivet 2004) bài báo khoa học научни чланак artículu científicu espublizáu en 2004 artigo científico 2004年论文 artykuł naukowy ২০০৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ мақолаи илмӣ 2004年論文 2004年论文 научни чланак 2004年論文 wetenschappelijk artikel vitenskapelig artikkel מאמר מדעי наукова стаття, опублікована в грудні 2004 2004年論文 2004년 논문 articol științific мақолаи илмӣ tieteellinen artikkeli научная статья 2004年の論文 επιστημονικό άρθρο 2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
p:P577
wds:Q33364359-95D677AB-8BB7-4D3F-8689-2C2B1021B4AB
wdt:P577
2004-12-30T00:00:00Z
p:P407
wds:Q33364359-1DE9AF85-4277-435C-9CA5-8EA5CF6CF179
wdt:P407
wd:Q1860
p:P2093
wds:Q33364359-909C76C6-C417-4CFD-A51A-5D6D252A993F wds:Q33364359-71ABF09B-33B6-4BDA-B62B-B94FBE3B4C3E wds:Q33364359-F5262B7F-F04A-4EF4-99EB-A6D46EFCCDC0 wds:Q33364359-DC2CF12B-034A-4462-8DF5-804124954B8C wds:Q33364359-CDC18F0E-7EF3-4CF3-89F0-7E27B7FD3C6A wds:Q33364359-D46A1DEF-D3B6-47EA-A6C4-BE142C49C9F3 wds:Q33364359-6DA230EA-7AD0-4AED-8CB4-79955B30F343 wds:Q33364359-3F749F99-A71C-4DAE-A2A9-C6ABC5D09954 wds:Q33364359-52D41331-A300-4BE1-8DA9-8DDE77837A8F wds:Q33364359-235772A2-E99F-46D1-8DE6-10A517CFD4A9 wds:Q33364359-04B6001F-B305-4AA8-BA5B-016F56163464 wds:Q33364359-06CF1D5A-30CD-492C-AD62-8B705A4F6749 wds:Q33364359-02913471-6BA2-47ED-9F07-26DD3B1DA657 wds:Q33364359-BB801AB0-F2F7-4047-A8DE-72C1C5A75E47 wds:Q33364359-B52BF133-6EF4-4F13-A511-FAC49E8B5B33 wds:Q33364359-A4E67896-F2EB-4719-9C7B-EE56E1B09CBD wds:Q33364359-A5126959-5B3A-45F2-A036-A54BC6696358 wds:Q33364359-9EE6945E-E043-4786-96A1-ADE85C8D9052
wdt:P2093
Dixie-Lee Esseltine Anastasia Ivanova Mary Jo Lehman Elizabeth G Trehu Don A Gabriel Jason M Collins Thomas C Shea Susan Natoli Fred J Kudrik Tammy Allred Marie Green Beverly S Mitchell Melissa D Hall Peter M Voorhees Julian Adams Hendrik W Van Deventer Anandhi R Johri Paul E Jones
rdfs:label
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
skos:prefLabel
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
schema:name
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
p:P50
wds:Q33364359-700B3F50-81FB-410C-A9F5-3C035ADE825C wds:Q33364359-72873281-7EED-4730-B16A-20B03E413CB6 wds:Q33364359-6FB054ED-5365-41A2-8A33-C33A57F0A425 wds:Q33364359-252A0CC6-1F93-4E11-862F-F6DF723849B9
wdt:P50
wd:Q109984365 wd:Q91807421 wd:Q91428664 wd:Q114530230
p:P1476
wds:Q33364359-EAE0CE5F-096E-4EB8-972C-F7AB175974E4
wdt:P1476
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
p:P304
wds:Q33364359-7AC7C215-4748-4FF6-A6A5-86769A7FA201
wdt:P304
3058-3065
p:P31
wds:Q33364359-F8101A61-57B8-4450-9D2A-7B877FEF469B
wdt:P31
wd:Q13442814
p:P921
wds:Q33364359-0C63515B-680F-4F87-87FF-CA81991DF007 wds:Q33364359-83009CF5-75B4-48CA-BB80-85DF54A729FF
wdt:P921
wd:Q18936 wd:Q5452194
p:P698
wds:Q33364359-71351BCE-B371-4C31-A9E5-08D9D91BBDC1
wdtn:P698
n11:15626743
wdt:P698
15626743
p:P1433
wds:Q33364359-CB654956-658D-4E82-AFA0-F31C459DFEDD
wdt:P1433
wd:Q885070
p:P433
wds:Q33364359-AA0B94F4-12C9-4EA3-BF07-38794C090E2C
p:P478
wds:Q33364359-292DE182-190C-4954-8FED-958FBF24E84D
wdt:P433
8
wdt:P478
105
p:P356
wds:Q33364359-0E5620AC-7D75-4CFD-B651-E4BCF7A11342
wdtn:P356
n12:BLOOD-2004-07-2911
wdt:P356
10.1182/BLOOD-2004-07-2911
p:P5875
wds:Q33364359-940400E9-ACD6-454E-B113-E1562FAD36C8
wdt:P5875
8103699